Plasma Biomarker in Amblyopia Patients

NCT ID: NCT05705778

Last Updated: 2023-01-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-01

Study Completion Date

2027-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective study aims to observe the predictive effect of peripheral blood plasma biomarker on the outcome of treatment in children with different types of amblyopia. We also investigated the mechanism of neuromodulation in the visual development of amblyopic children.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Amblyopia

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

amblyopia plasma biomarker prediction treatment outcome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Strabismic

standard amblyopia treatment

Intervention Type PROCEDURE

amblyopia treatment following international guidelines and genetic tests.

Anisometropic

standard amblyopia treatment

Intervention Type PROCEDURE

amblyopia treatment following international guidelines and genetic tests.

Isoametropic

standard amblyopia treatment

Intervention Type PROCEDURE

amblyopia treatment following international guidelines and genetic tests.

Visual deprivation

standard amblyopia treatment

Intervention Type PROCEDURE

amblyopia treatment following international guidelines and genetic tests.

Mixed group

standard amblyopia treatment

Intervention Type PROCEDURE

amblyopia treatment following international guidelines and genetic tests.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

standard amblyopia treatment

amblyopia treatment following international guidelines and genetic tests.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

plasma biomarker test

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosed with amblyopia
* 3-12 years of age
* Able to tolerate amblyopia treatment
* Agree to be involved in this study and agree to have a follow up visit every 3 months.

Exclusion Criteria

* Have previous treatment history before
* Have pathological ocular anomalies known to cause reduced visual acuity
* Have previous psychiatric, visual or neurological disorders
* Have eccentric fixation and/or abnormal retinal correspondence
* Have attention disorder and learning disability that cannot comprehend psychophysical test instructions given and/or consent for themselves
Minimum Eligible Age

3 Years

Maximum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Zhongshan Ophthalmic Center, Sun Yat-sen University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jingrong Li

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Ophthalmic Center

Guangzhou, Guangdong, China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Jinrong Li, PhD

Role: CONTACT

Phone: 86-020-87330351

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Jinrong Li, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2022KYPJ102

Identifier Type: -

Identifier Source: org_study_id